Chimerix (NASDAQ:CMRX) Receives Neutral Rating from Wedbush
Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “neutral” rating reissued by Wedbush in a research note issued on Wednesday, Marketbeat reports. They presently have a $8.55 target price on the biopharmaceutical company’s stock, up from their prior target price of $7.00. Wedbush’s target price points to a potential upside of 1.42% from the […]
Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “neutral” rating reissued by Wedbush in a research note issued on Wednesday, Marketbeat reports. They presently have a $8.55 target price on the biopharmaceutical company’s stock, up from their prior target price of $7.00. Wedbush’s target price points to a potential upside of 1.42% from the […]
